Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent.~* Men or women aged 18-80 years.~* A primary psychiatric diagnosis of major depressive disorder (MDD), by Diagnostic and Statistical Manual-5th ed (DSM-5) using the Mini International Neuropsychiatric Interview (MINI v.7.0).~* A Screening and Baseline visit Inventory of Depressive Symptoms, Clinician rated (IDS-C30) total score ≥ 25.~* Currently overweight at screening, defined as BMI \> 25 kg/m2.~* Screening visit high-sensitivity C-reactive protein concentration ≥ 3 mg/L.~* Willing to not significantly modify their diet from the time they sign consent through the end of study participation.~Exclusion Criteria:~* Use of any psychotropic agents within 2 weeks of baseline or at any time during the study, with the exception of prescription hypnotics (eszopiclone, zaleplon, zolpidem, suvorexant, ramelteon), diphenhydramine, or a stable daily dose of a benzodiazepine.~* Breastfeeding or pregnant women, women intending to become pregnant within 6 months of the screening visit, or women of child bearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, intrauterine device (IUD), status-post tubal ligation, or partner with vasectomy)~* Patients who, in the investigator's judgement, pose a current, serious suicidal or homicidal risk.~* Serious or unstable medical illness that in the investigator's opinion could compromise response to treatment or interpretation of study results.~* History of seizure disorder, except for childhood febrile seizures.~* Meeting DSM-5 criteria at any point in their lifetime, for any of the following: Neurocognitive Disorder, Psychotic Disorder, Bipolar disorder, Anorexia Nervosa~* Meeting DSM-5 criteria in the 3 months prior to the screening visit for any Substance Use Disorder (except nicotine or caffeine).~* Meeting DSM-5 criteria at screening for current obsessive compulsive disorder or bulimia nervosa.~* Presence of psychotic features at any time during the current major depressive episode.~* Any conditions or medications (within 1 week of baseline or during the trial) that might confound the biomarker findings, including: Regular ingestion of NSAIDs or Cyclooxygenase-2 (COX-2) inhibitors, or any use of oral steroids, immunosuppressants, interferon, chemotherapy, or anticoagulants (Patients will be instructed not to take a nonsteroidal antiinflammatory drug (NSAID) or COX-2 inhibitor in the 24 hours prior to a biomarker assessment visit), Malignancy not in remission for at least 1 year, Active autoimmune disorder or inflammatory bowel disease, Insulin-dependent diabetes mellitus.~* History of allergy to PUFA supplements.~* Laboratory evidence of undiagnosed hypothyroidism or change in treatment for hypothyroidism in the 3 months prior to screening.~* Patients who have failed to respond during the course of their current major depressive episode to \>4 adequate antidepressant trials, defined as six weeks or more of treatment with the FDA-defined minimally effective dose.~* Patients who have taken a supplement of at least 1 g/day of omega 3 fatty acids for at least 6 weeks during the current major depressive episode.~* Patients who have had electroconvulsive therapy (ECT) during the current depressive episode or within 6 months of the screening visit.~* Patients who have taken supplements with omega-3 fatty acids (see Appendix A for list of products) within sixty (60) days of the screening visit.~* Patients who, at baseline, are consuming a diet that contains more than 3g/day of omega-3 FA, or who consume more than 3 meals of fatty fish per week.~* Patients who have a history of a bleeding disorder.~* Patients who have participated in another clinical trial of an investigational medication within 1 month of the screening visit.~* Patients who are currently in psychotherapy that was initiated within 90 days prior to the study screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Soybean oil placebo capsules, 4 capsules daily for 12 weeks
- EPA 1 g/day (Type: EXPERIMENTAL): Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
- EPA 2 g/day (Type: EXPERIMENTAL): Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
- EPA 4 g/day (Type: EXPERIMENTAL): Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete